282 related articles for article (PubMed ID: 25931333)
1. Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model.
Reid GA; Darvesh S
Neuroscience; 2015 Jul; 298():424-35. PubMed ID: 25931333
[TBL] [Abstract][Full Text] [Related]
2. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
[TBL] [Abstract][Full Text] [Related]
3. Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease.
Hüttenrauch M; Baches S; Gerth J; Bayer TA; Weggen S; Wirths O
J Alzheimers Dis; 2015; 44(4):1291-302. PubMed ID: 25408216
[TBL] [Abstract][Full Text] [Related]
4. Interaction of Exogenous Butyrylcholinesterase with β-Amyloid Plaques in 5XFAD/Butyrylcholinesterase-Knockout Mouse Brain.
Reid GA; Darvesh S
Curr Alzheimer Res; 2021; 18(6):470-481. PubMed ID: 34455970
[TBL] [Abstract][Full Text] [Related]
5. Reduced fibrillar β-amyloid in subcortical structures in a butyrylcholinesterase-knockout Alzheimer disease mouse model.
Darvesh S; Reid GA
Chem Biol Interact; 2016 Nov; 259(Pt B):307-312. PubMed ID: 27091549
[TBL] [Abstract][Full Text] [Related]
6. Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models.
Liao F; Zhang TJ; Jiang H; Lefton KB; Robinson GO; Vassar R; Sullivan PM; Holtzman DM
Acta Neuropathol Commun; 2015 Nov; 3():70. PubMed ID: 26556230
[TBL] [Abstract][Full Text] [Related]
7. Genetic Deletion of Tumor Necrosis Factor-α Attenuates Amyloid-β Production and Decreases Amyloid Plaque Formation and Glial Response in the 5XFAD Model of Alzheimer's Disease.
Paouri E; Tzara O; Zenelak S; Georgopoulos S
J Alzheimers Dis; 2017; 60(1):165-181. PubMed ID: 28826177
[TBL] [Abstract][Full Text] [Related]
8. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
9. Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models.
Reinert J; Richard BC; Klafki HW; Friedrich B; Bayer TA; Wiltfang J; Kovacs GG; Ingelsson M; Lannfelt L; Paetau A; Bergquist J; Wirths O
Acta Neuropathol Commun; 2016 Mar; 4():24. PubMed ID: 26955942
[TBL] [Abstract][Full Text] [Related]
10. Intracellular amyloid-β accumulation in calcium-binding protein-deficient neurons leads to amyloid-β plaque formation in animal model of Alzheimer's disease.
Moon M; Hong HS; Nam DW; Baik SH; Song H; Kook SY; Kim YS; Lee J; Mook-Jung I
J Alzheimers Dis; 2012; 29(3):615-28. PubMed ID: 22269161
[TBL] [Abstract][Full Text] [Related]
11. Microglia contributes to plaque growth by cell death due to uptake of amyloid β in the brain of Alzheimer's disease mouse model.
Baik SH; Kang S; Son SM; Mook-Jung I
Glia; 2016 Dec; 64(12):2274-2290. PubMed ID: 27658617
[TBL] [Abstract][Full Text] [Related]
12. Lack of human-like extracellular sortilin neuropathology in transgenic Alzheimer's disease model mice and macaques.
Zhou FQ; Jiang J; Griffith CM; Patrylo PR; Cai H; Chu Y; Yan XX
Alzheimers Res Ther; 2018 Apr; 10(1):40. PubMed ID: 29690919
[TBL] [Abstract][Full Text] [Related]
13. Deletion of the Inflammasome Sensor Aim2 Mitigates Aβ Deposition and Microglial Activation but Increases Inflammatory Cytokine Expression in an Alzheimer Disease Mouse Model.
Wu PJ; Hung YF; Liu HY; Hsueh YP
Neuroimmunomodulation; 2017; 24(1):29-39. PubMed ID: 28618410
[TBL] [Abstract][Full Text] [Related]
14. Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation.
Kummer MP; Hermes M; Delekarte A; Hammerschmidt T; Kumar S; Terwel D; Walter J; Pape HC; König S; Roeber S; Jessen F; Klockgether T; Korte M; Heneka MT
Neuron; 2011 Sep; 71(5):833-44. PubMed ID: 21903077
[TBL] [Abstract][Full Text] [Related]
15. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
16. N-truncated Aβ
Wirths O; Walter S; Kraus I; Klafki HW; Stazi M; Oberstein TJ; Ghiso J; Wiltfang J; Bayer TA; Weggen S
Alzheimers Res Ther; 2017 Oct; 9(1):80. PubMed ID: 28978359
[TBL] [Abstract][Full Text] [Related]
17. Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease.
Macdonald IR; Maxwell SP; Reid GA; Cash MK; DeBay DR; Darvesh S
J Alzheimers Dis; 2017; 58(2):491-505. PubMed ID: 28453492
[TBL] [Abstract][Full Text] [Related]
18. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
[TBL] [Abstract][Full Text] [Related]
19. Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse.
Dinkins MB; Enasko J; Hernandez C; Wang G; Kong J; Helwa I; Liu Y; Terry AV; Bieberich E
J Neurosci; 2016 Aug; 36(33):8653-67. PubMed ID: 27535912
[TBL] [Abstract][Full Text] [Related]
20. Impact of CRFR1 Ablation on Amyloid-β Production and Accumulation in a Mouse Model of Alzheimer's Disease.
Campbell SN; Zhang C; Roe AD; Lee N; Lao KU; Monte L; Donohue MC; Rissman RA
J Alzheimers Dis; 2015; 45(4):1175-84. PubMed ID: 25697705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
